Knowledge and Networking Breakfast Forum

Thursday, June 15, 2017

  

When:    Thursday, June 15th, 2017

Where:  Fasken Martineau DuMoulin LLP
              333 Bay Street, Suite 2400, Toronto, Ontario (Map Below)

Time:    
7:30 am - Registration/ Breakfast 
8:00 am - 9:30 am - Presentations
9:30 am – 10:00 am – Networking  

(having trouble opening the registration link, click here to update your browser)

$10 for members
$5 for students members
$30 for non members

Online Webinar Option Available
LSO continues our live webinar of the Breakfast meeting. Register here and select the "Online Webinar" ticket to join in.
(having trouble opening the registration link, click here to update your browser)

 

Speakers & Topic:  

Member Marathon

  • MAGNUS Personnel Corporation

MAGNUS Personnel is a highly-specialized headhunting firm operating in the medical, clinical research, life sciences, B2B industrial and technology sectors.
More than 150 clients across Canada and the US trust MAGNUS to locate and engage North America’s most talented people for their businesses. With an impressive 95% hiring success rate, MAGNUS is positioning itself as an industry leader in the medical and life sciences space. 
For more information, visit http://www.magnuspersonnel.com/.

  •  Scientus Pharma

 

  • SGS Life Science Services

SGS Life Sciences is a leading contract service organization providing analytical development, biologics characterization, biosafety and quality control testing.  
With the largest network of 21 laboratories in 11 countries, services include: analytical chemistry, microbiology, stability studies, bioanalysis, extractables/leachables, virology and protein analysis. Additionally, we offer Phase I-IV clinical services. SGS is a fully GMP facility and has been inspected by both Health Canada and FDA.

 

  • Biotagenics Inc.

Biotagenics is a Canadian company with a clinical microbiomics platform. Its mission is to develop effective  precision treatment for inflammatory bowel disease (IBD) by targeting the underlying dysbiosis of the gut microbiota. Using a proprietary microbiome and proteome discovery platform Biotagenics has identified biomarkers and characterized the gut microbiota that differentiate with high sensitivity between clinical subtypes of IBD. A number of pathobionts associated with IBD have been identified and species-specific antibodies, clinical nutrition products, as well as companion diagnostics are being developed for IBD diagnosis and therapy.